The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: Insights from the e-select 64-71 (multicenter post-market surveillance) registry

Alexandre Abizaid, J Costa, Adrian Banning, Antonio Bartorelli, Vladimir Dzavik, Stephen Ellis, Runlin Gao, David Holmes Jr, Muyng Ho Jeong, Victor Legrand, Franz-Josef Neumann, Maria Nyakern, Amy Orlick, Christian Spaulding, Stephen Worthley, Philip Urban, Derek Chew

    Research output: Contribution to journalArticlepeer-review

    15 Citations (Scopus)

    Abstract

    This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. There is paucity of consistent data on DES for the treatment of ISR, especially, DES ISR. The e-SELECT (Multicenter Post-Market Surveillance) registry is a Web-based, multicenter and international registry encompassing virtually all subsets of patients and lesions treated with at least 1 SES during the period from 2006 to 2008. We enrolled in this pre-specified subanalysis all patients with at least 1 clinically relevant BMS or DES ISR treated with SES. Primary endpoint was major adverse cardiac events and stent thrombosis rate at 1 year. Of 15,147 patients enrolled, 1,590 (10.5%) presented at least 1 ISR (BMS group, n = 1,235, DES group, n = 355). Patients with DES ISR had higher incidence of diabetes (39.4% vs. 26.9%, p < 0.001), renal insufficiency (5.8% vs. 2.3%, p = 0.003), and prior coronary artery bypass graft (20.5% vs. 11.8%, p < 0.001). At 1 year, death (1.4% for BMS vs. 2.1% for DES, p = 0.3) and myocardial infarction (2.4% for BMS and 3.3% for DES, p = 0.3) rates were similar, whereas ischemia-driven target lesion revascularization and definite/probable late stent thrombosis were higher in patients with DES ISR (6.9% vs. 3.1%, p = 0.003, and 1.8% vs. 0.5%, p = 0.04, respectively). Use of SES for either BMS or DES ISR treatment is safe and associated with low target lesion revascularization recurrence and no apparent safety concern.

    Original languageEnglish
    Pages (from-to)64-71
    Number of pages8
    JournalJACC: Cardiovascular Interventions
    Volume5
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 2012

    Keywords

    • in-stent restenosis
    • sirolimus-eluting stent(s)
    • target lesion revascularization

    Fingerprint Dive into the research topics of 'The sirolimus-eluting cypher select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: Insights from the e-select 64-71 (multicenter post-market surveillance) registry'. Together they form a unique fingerprint.

    Cite this